Cargando…

Predicting treatment outcomes using (18)F-FDG PET biomarkers in patients with non-small-cell lung cancer receiving chemoimmunotherapy

BACKGROUND: Predictive markers for treatment response and survival outcome have not been identified in patients with advanced non-small-cell lung cancer (NSCLC) receiving chemoimmunotherapy. We aimed to evaluate whether imaging biomarkers of (18)F-fluorodeoxyglucose ((18)F-FDG) positron emission tom...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Chang Gon, Hwang, Sang Hyun, Kim, Kyung Hwan, Yoon, Hong In, Shim, Hyo Sup, Lee, Ji Hyun, Han, Yejeong, Ahn, Beung-Chul, Hong, Min Hee, Kim, Hye Ryun, Cho, Byoung Chul, Cho, Arthur, Lim, Sun Min
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2022
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8753071/ https://www.ncbi.nlm.nih.gov/pubmed/35035536 http://dx.doi.org/10.1177/17588359211068732

Ejemplares similares

A phase II study of poziotinib in patients with recurrent and/or metastatic head and neck squamous cell carcinoma
por: Lee, Ji Hyun, et al.
Publicado: (2021)

Real-World Analysis of the Efficacy of Rebiopsy and EGFR Mutation Test of Tissue and Plasma Samples in Drug-Resistant Non-Small Cell Lung Cancer
por: Hong, Min Hee, et al.
Publicado: (2019)

Real World Characteristics and Clinical Outcomes of HER2-Mutant Non–Small Cell Lung Cancer Patients Detected by Next-Generation Sequencing
por: Ahn, Beung-Chul, et al.
Publicado: (2023)

Distinct Characteristics and Clinical Outcomes to Predict the Emergence of MET Amplification in Patients with Non-Small Cell Lung Cancer Who Developed Resistance after Treatment with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
por: Ahn, Beung-Chul, et al.
Publicado: (2021)

Comprehensive analysis of the characteristics and treatment outcomes of patients with non-small cell lung cancer treated with anti-PD-1 therapy in real-world practice
por: Ahn, Beung-Chul, et al.
Publicado: (2019)

Analyses of CNS Response to Osimertinib in Patients with T790M-Positive Advanced NSCLC from ASTRIS Korean Subset, Open-Label Real-World Study
por: Ahn, Beung-Chul, et al.
Publicado: (2021)

The feasibility and safety of radical esophagectomy in patients receiving neoadjuvant chemoradiotherapy with pembrolizumab for esophageal squamous cell carcinoma
por: Park, Seong Yong, et al.
Publicado: (2020)

Clinical correlation of metabolic parameters on (18)F-FDG PET/CT in idiopathic frozen shoulder
por: Won, Kyoung Sook, et al.
Publicado: (2017)

Genomic profiling of lung adenocarcinoma patients reveals therapeutic targets and confers clinical benefit when standard molecular testing is negative
por: Lim, Sun Min, et al.
Publicado: (2016)

Detection of activating and acquired resistant mutation in plasma from EGFR-mutated NSCLC patients by peptide nucleic acid (PNA) clamping-assisted fluorescence melting curve analysis
por: Kim, Chang Gon, et al.
Publicado: (2017)

Screening of ROS1 Rearrangements in Lung Adenocarcinoma by Immunohistochemistry and Comparison with ALK Rearrangements
por: Cha, Yoon Jin, et al.
Publicado: (2014)

Detection of primary sites in unknown primary tumors using FDG-PET or FDG-PET/CT
por: Park, Jong Sun, et al.
Publicado: (2011)

The Development of AXL Inhibitors in Lung Cancer: Recent Progress and Challenges
por: Sang, Yun Beom, et al.
Publicado: (2022)

Hypertrophic Cardiomyopathy Complicated by Left Ventricular Apical Necrosis and Aneurysm in a Young Man: FDG-PET Findings
por: Park, Jong-Seon, et al.
Publicado: (2007)

The clinical implications of FDG-PET/CT differ according to histology in advanced gastric cancer
por: Chon, Hong Jae, et al.
Publicado: (2018)

Patient-Derived Cells to Guide Targeted Therapy for Advanced Lung Adenocarcinoma
por: Kim, Seok-Young, et al.
Publicado: (2019)

Concordance of programmed death-ligand 1 expression between primary and metastatic non-small cell lung cancer by immunohistochemistry and RNA in situ hybridization
por: Kim, Hye Ryun, et al.
Publicado: (2017)

Brief Report: Heterogeneity of Acquired Resistance Mechanisms to Osimertinib and Savolitinib
por: Lim, Sun Min, et al.
Publicado: (2021)

Incidental Breast Lesions Identified by (18)F-FDG PET/CT: Which Clinical Variables Differentiate between Benign and Malignant Breast Lesions?
por: Shin, Kyung Min, et al.
Publicado: (2015)

Prognostic implications of PD-L1 expression in patients with angiosarcoma
por: Lee, Jii Bum, et al.
Publicado: (2021)

Effectiveness of pegfilgrastim prophylaxis in preventing febrile neutropenia during R-FC chemoimmunotherapy for chronic lymphocytic leukemia: A multicenter prospective phase II study
por: Jeon, Youngwoo, et al.
Publicado: (2023)

Splenic uptake on FDG PET/CT correlates with Kikuchi-Fujimoto disease severity
por: Seong, Hye, et al.
Publicado: (2021)

Frontline treatment with chemoimmunotherapy for limited-stage ocular adnexal MALT lymphoma with adverse factors: a phase II study
por: Kim, Sung-Yong, et al.
Publicado: (2017)

FDG Uptake in PET by Bladder Hernia Simulating Inguinal Metastasis
por: Park, Sung Hee, et al.
Publicado: (2007)

Tumor microenvironment dictates regulatory T cell phenotype: Upregulated immune checkpoints reinforce suppressive function
por: Kim, Hye Ryun, et al.
Publicado: (2019)

Genome-wide identification of differentially methylated promoters and enhancers associated with response to anti-PD-1 therapy in non-small cell lung cancer
por: Cho, Jae-Won, et al.
Publicado: (2020)

Assessment of Chemotherapy Response Using FDG-PET in Pediatric Bone Tumors: A Single Institution Experience
por: Kim, Dong Hwan, et al.
Publicado: (2011)

Comprehensive analyses of immunodynamics and immunoreactivity in response to treatment in ALK-positive non-small-cell lung cancer
por: Pyo, Kyoung-Ho, et al.
Publicado: (2020)

Correlation between EGFR gene mutation, cytologic tumor markers, 18F-FDG uptake in non-small cell lung cancer
por: Cho, Arthur, et al.
Publicado: (2016)

The Clinical Meaning of Benign Colon Uptake in (18)F-FDG PET: Comparison with Colonoscopic Findings
por: Roh, Sun Hee, et al.
Publicado: (2012)

Transglutaminase 2 Expression Predicts Progression Free Survival in Non-Small Cell Lung Cancer Patients Treated with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor
por: Jeong, Jae-Heon, et al.
Publicado: (2013)

The importance of enhancer methylation for epigenetic regulation of tumorigenesis in squamous lung cancer
por: Cho, Jae-Won, et al.
Publicado: (2022)

The Clinical Usefulness of (18)F-Fluorodeoxyglucose Positron Emission Tomography (PET) to Predict Oncologic Outcomes and PET-Based Radiotherapeutic Considerations in Locally Advanced Nasopharyngeal Carcinoma
por: Yoon, Hong In, et al.
Publicado: (2016)

R-CHOP chemoimmunotherapy followed by autologous transplantation for the treatment of diffuse large B-cell lymphoma
por: Lee, Hong Ghi, et al.
Publicado: (2014)

Targeted sequencing identifies genetic alterations that confer primary resistance to EGFR tyrosine kinase inhibitor (Korean Lung Cancer Consortium)
por: Lim, Sun Min, et al.
Publicado: (2016)

Comparison of Clinical Outcomes between Idiopathic Frozen Shoulder and Diabetic Frozen Shoulder After a Single Ultrasound-Guided Intra-Articular Corticosteroid Injection
por: Cho, Chul-Hyun, et al.
Publicado: (2020)

Development of a new risk stratification system for patients with newly diagnosed multiple myeloma using R-ISS and (18)F-FDG PET/CT
por: Cho, Hee Jeong, et al.
Publicado: (2021)

The Effect of Xanthigen on the Expression of Brown Adipose Tissue Assessed by (18)F-FDG PET
por: Kim, Kwang-Min, et al.
Publicado: (2016)

Cluster analysis of autoencoder-extracted FDG PET/CT features identifies multiple myeloma patients with poor prognosis
por: Lee, Hyunjong, et al.
Publicado: (2023)

Metabolic tumour volume on (18)F-FDG PET/CT predicts extended pathological T stages in patients with renal cell carcinoma at staging
por: Kim, Dongwoo, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_6ef7ja1tf4975rsa88kohgf3qn